Characteristics of patients in the placebo arm and the pooled treatment arms of tocilizumab, at baseline and after 1 year (mean±SD, unless indicated otherwise)
| Baseline (BL) | 1 Year | |||
|---|---|---|---|---|
| Characteristics | BL PL | BL TCZ | 1-yr PL | 1-yr TCZ |
| N | 117 | 414 | 117 | 414 |
| Age (years) | 50.3±12.3 | 52.5±11.5 | - | - |
| Disease duration (years) | 8.57±8.5 | 8.85±7.8 | - | - |
| Rheumatoid factor (% positive) | 83.7 | 81.8 | - | - |
| Swollen joint count (0–28) | 11.4±5.0 | 12.2±5.6 | 4.4±4.7 | 3.3±3.4** |
| Tender joint count (0–28) | 14.2±6.4 | 15.5±6.6* | 5.7±5.7 | 4.0±5.2*** |
| Patient global (0–100 mm) | 61.3±22.0 | 59.8±23.3 | 37.5±23.2 | 31.4±23.5** |
| Evaluator global (0–100 mm) | 59.0±17.7 | 62.5±16.1* | 24.4±17.6 | 18.8±16.6** |
| Pain (0–100 mm) | 52.1±21.6 | 53.2±22.7 | 33.3±20.5 | 28.7±21.9** |
| C-reactive protein (mg/dl) | 2.0±2.3 | 2.3±2.6 | 1.4±1.7 | 0.5±1.2*** |
| Erythrocyte sedimentation rate (mm/h) | 44.4±23.5 | 46.4±24.9 | 33.8±22.0 | 13.5±15.8*** |
| Disease activity score 28 (DAS28) | 6.3±0.8 | 6.5±0.9* | 4.2±1.3 | 2.9±1.4*** |
| Simplified disease activity index (SDAI) | 39.6±12.0 | 42.3±13.2* | 17.7±12.0 | 12.8±10.3*** |
| Clinical disease activity index (CDAI) | 37.6±11.3 | 40.0±12.4 | 16.3±11.3 | 12.3±10.0*** |
| Health Assessment Questionnaire (HAQ) | 1.5±0.6 | 1.5±0.6 | 1.0±0.6 | 0.9±0.6 |
| Genant-modified total Sharp score (TGSS) | 27.1±28.3 | 27.1±26.5 | 28.0±28.5 | 27.4±26.7 |
| Change in TGSS | NA | NA | 0.90±1.92 | 0.29±0.96† |